# $LLY Catalyst Posts & Social Intelligence Recap — September 22, 2026

> **Asset:** $LLY  
> **Date:** 2026-09-22 (September 22, 2026)  
> **Canonical URL:** https://cryptitalk.com/tokens/lly/2026-09-22  
> **Token Profile:** https://cryptitalk.com/tokens/lly.md  
> **Market Rankings:** https://cryptitalk.com/rankings.md  

---



## Curated Viral Posts & Community Evidence


### Post #1 by @Pharmdca
> **Author:** Pharmdca ([@Pharmdca](https://x.com/Pharmdca))  
> **Metrics:** 70 likes · 12 retweets · 2 comments · 19.4K views  

> **Posted:** 2026-09-22T11:27:58+00:00  


> **Source Link:** [https://x.com/Pharmdca/status/2102359245320855564](https://x.com/Pharmdca/status/2102359245320855564)  


> **Visual Note:** The image displays Table 1, titled "Adverse events in key global SURMOUNT studies for overweight/obesity management," comparing side effects across four SURMOUNT trials (SURMOUNT-1, -2, -3, and -4) for tirzepatide (TZP) and placebo groups, listing events like intervention counts, participants with ≥1 AE, deaths, and discontinuations over specified weeks.

This table supports the post's comparison of $VKTX's VK2735 to Eli Lilly's ($LLY) tirzepatide (SURMOUNT trials) by showing the safety/tolerability profile of the relevant comparator drug across its clinical program.  

> 
> "$VKTX
 this is how VK2735 stands against 
$LLY
 tirzepatide/retatrutide

1) VK2735’s weekly 17.5 mg cohort reached 22% weight loss at Week 33 with no plateau

Tirzepatide (Zepbound) Phase 3: ~22.5% at Week 72

Retatrutide Phase 2: ~24% at Week 48

2) VK2735 is already in the same"




---

*Generated by Context Pilot Social Intelligence Engine.*